SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida

CompletedOBSERVATIONAL
Enrollment

1,135

Participants

Timeline

Start Date

October 17, 2020

Primary Completion Date

July 25, 2021

Study Completion Date

July 25, 2021

Conditions
Coronavirus Infection
Interventions
DIAGNOSTIC_TEST

SARS-CoV-2 Antibody Analysis

10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.

DIAGNOSTIC_TEST

Weck-cel Swab Collection

A Weck-cel swab will be used to collect secretions from the mucosal epithelium

BEHAVIORAL

Web Based Questionnaire

A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT04596579 - SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida | Biotech Hunter | Biotech Hunter